

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**




Fig. 1a





Fig. 1b





Fig. 1c


Fold expansion (2w) CD34+

Fig. 2a


Fold expansion (2w) CD34+/38-

Fig. 2b


Fold expansion (2w) CD34+/Lin-

Fig. 2c

5/17

CD34+




Fig. 3a

CD34+/38-




Fig. 3b

CD34+/Lin-




Fig. 3c




Fig. 4






Fig. 5a Negative Control,
IgG PE/IgG FITC



Control, 2 weeks, CD34⁺ Lin⁻

Quad	% Gated
UL	1.60
UR	95.79
LL	0.03
LR	2.58


Fig. 5b



RA antagonist, 10⁻⁵M, 2 weeks, CD34⁺ Lin⁻

Quad	% Gated
UL	36.89
UR	62.77
LL	0.14
LR	0.20


Fig. 5c



RA antagonist, 10⁻⁷M, 11 weeks, CD34⁺ Lin⁻

Quad	% Gated
UL	1.88
UR	94.95
LL	0.15
LR	3.03

Fig. 5d



RA antagonist, 10⁻⁵M, 11 weeks, CD34⁺ Lin⁻

Quad	% Gated
UL	5.15
UR	79.08
LL	0.07
LR	15.71

Fig. 5e




Fig. 6a




Fig. 6b




Fig. 7




Fig. 8a




Fig. 8b




Fig. 9a




Fig. 9b



Fig. 9c




Fig. 10a




Fig. 10b




Fig. 10c



Fig. 10d

Fig. 11a



Fig. 11c



Fig. 11e



Fig. 11b



Fig. 11d




Fig. 11f



11/17

3 weeks-(34/Lin FACS analysis)

Control-cytokines only



File:ex.43(3w)3.12.02.005


SampleID:

X Parameter:FL1-H(Log)

Y Parameter:FL2-H(Log)

Quad	% Gated
UL	0.04
UR	98.99
LL	0.22
LR	0.75

RAR antagonist 10-7M



File:ex.43(3w)3.12.02.011


SampleID:

X Parameter:FL1-H(Log)

Y Parameter:FL2-H(Log)

Quad	% Gated
UL	8.19
UR	85.41
LL	0.44
LR	5.96

RAR+RXR antagonist 10-7M



File:ex.43(3w)3.12.02.020

SampleID:

X Parameter:FL1-H(Log)

Y Parameter:FL2-H(Log)

Quad	% Gated
UL	19.75
UR	79.79
LL	0.09
LR	0.37


Fig. 12a

12/17

5 weeks-(34/Lin FACS analysis)

*Control(only cytokines) -The number of cells was not sufficient for FACS analysis.

RAR antagonist 10-7M



File:ex.42(5w)18.12.02.008

Sample ID:

X Parameter:FL1-H(Log)

Y Parameter:FL2-H(Log)

Quad % Gated


UL 3.19

UR 91.04

LL 0.39

LR 5.37

RAR+RXR antagonist 10-7M



File:ex.42(5w)18.12.02.010

Sample ID:

X Parameter:FL1-H(Log)

Y Parameter:FL2-H(Log)

Quad % Gated

UL 17.38

UR 81.18

LL 0.08

LR 1.36

Fig. 12b




Fig. 13a




Fig. 13b




Fig. 13c




Fig. 13d

CFU




Fig. 13e




Fig. 14




Fig. 15




Fig. 16






Fig. 17

FACS analysis34/38Control-cytokines only

Quad	% Gated
UL	0.14
UR	99.44
LL	0.12
LR	0.30

Nicotinamide 5 mM

Quad	% Gated
UL	34.67
UR	62.28
LL	1.24
LR	1.80

Fig. 18a


FACS analysis: CD34/Lin

Fig. 18b



FACS analysis: 34/HLA-DR+38

Fig. 18c